New Yorker reporter Dhruv Khullar spotlights how researchers from across MIT are using AI to advance drug development. Khullar highlights the MIT Jameel Clinic, the Broad Institute and various faculty members for their efforts in bridging the gap between AI and drug research. “With AI, we’re getting that much more efficient at finding molecules—and in some cases creating them,” says Prof. James Collins. “The cost of the search is going down. Now we really don’t have an excuse.”
MIT alumni Mike Ng and Nikhil Buduma founded Ambiance, which has developed an “AI-powered platform geared towards improving documentation processes in medicine,” reports Fortune’s Allie Garfinkle. “In a world filled with AI solutions in search of a problem, Ambience is focusing on a pain point that just about any doctor will attest to (after all, who likes filling out paperwork?),” writes Garfinkle.
Researchers at MIT and elsewhere have developed a new device “designed to detect the signs of an overdose and automatically deliver a dose of naloxone in as little as 10 seconds,” reports Tom Hawking for Popular Science. “The device [which has an associated smartphone app] also has a built-in alert system with auditory and tactile signals to wake the user, providing an alternative for those without smartphones or with uncharged devices,” says Prof. Giovanni Traverso.
Interesting Engineering reporter Shubhangi Dua describes a new implantable device developed by MIT researchers that can detect and automatically treat an opioid overdose. “Having an automated robotic system that can sense and reverse opiate overdose could be transformational,” says Prof. Giovanni Traverso, “particularly for high-risk populations.”
MIT scientists have developed an implantable sensor that could “detect the signs of an overdose and automatically deliver a dose of naloxone in as little as 10 seconds,” reports Tom Hawking for Popular Science. "The long-term benefits of preventing fatal overdoses and reducing healthcare costs related to overdose treatment are significant factors that support the value of this technology,” explains Prof. Giovanni Traverso.
Prof. Jonathan Gruber speaks with WGBH’s Craig LeMoult about the bidding process around seven Massachusetts hospitals being sold by Steward Health Care. “I hope that someone innovative can figure out a way to take these existing assets…and turn them into an effective competitor to the [Mass General Brigham] network because we need more competition in health care in Massachusetts,” says Gruber.
Writing for Forbes, lecturer Guadalupe Hayes-Mota '08, SM '16, MBA '16 explores the role of artificial intelligence and biotechnology in transforming the healthcare industry specifically for venture capitalists (VCs). “The fusion of AI and biotechnology presents a wealth of opportunities for venture capitalists,” writes Hayes-Mota. “By staying attuned to emerging trends and adopting strategies for impactful investments, VCs can drive innovation and create transformative changes in healthcare.”
Prof. Hugh Herr joins the BBC’s Shiona McCallum to discuss a program by the K. Lisa Yang Center for Bionics aimed at bringing prosthetics to those who suffered forced amputations during the Sierra Leone Civil War. “When we train a young person on how to construct an arm or leg prothesis we’ve impacted the country for solidly forty years,” Herr says. “That person’s going to be living in that country and contributing to their community for a very long time. That’s exciting.”
The Engine Ventures' CEO and Managing partner Katie Rae talks to Forbes’ Alex Knapp about its recent round of fundraising for investments in startups focused on sustainability, health and infrastructure. Rae also sees opportunities in quantum computing and other new hardware, saying “power and climate and compute all go together.”
Katie Rae, CEO and managing partner of the Engine Ventures, speaks with Boston Globe reporter Aaron Pressman about The Engine Ventures’ third investment fund, which remains focused on “helping early-stage startups develop and commercialize ‘tough tech,’ which can include anything from fusion power generators to cement made without fossil fuels.” Rae notes: “You see this dynamism not just for climate, but for all things manufacturing, whether it’s biotech, whether it’s AI chips, it is about as an exciting moment as you could get for what we do.”
Prof. Regina Barzilay spoke at The Futurist Summit: The Age of AI – an event hosted by The Washington Post – about the influence of AI in medicine. “When we're thinking today how many years it takes to bring new technologies [to market], sometimes it's decades if we’re thinking about drugs, and very, very slow,” Barzilay explains. “With AI technologies, you've seen how fast the technology that you're using today is changing.”
Prof. Bob Langer and Prof. Giovanni Traverso have co-founded Syntis Bio, a biotech company that will use technology to “coat the stomach and potentially other organ surfaces, [change] the way that drugs are absorbed or, in the case of obesity, which hormones are triggered,” reports Allison DeAngelis for STAT.
Prof. Regina Barzilay joins The Economist’s “Babbage” podcast to discuss how artificial intelligence could enable health care providers to understand and treat diseases in new ways. Host Alok Jha notes that Barzilay is determined to “overcome those challenges that are standing in the way of getting AI models to become useful in health care.” Barzilay explains: “I think we really need to change our mindset and think how we can solve the many problems for which human experts were unable to find a way forward.”
Forbes selects innovators for the list’s Healthcare & Science category, written by senior contributor Yue Wang. On the list is MIT PhD candidate Yuzhe Yang, who studies AI and machine learning technologies capability to monitor and diagnose illnesses such as Parkinson's disease.
In an article for Fast Company, Lecturer Guadalupe Hayes-Mota offers five takeaways concerning the potential impact of AI on healthcare. Understanding AI’s healthcare potential “is crucial for business leaders and policymakers to foster an environment where AI and other analytics tools enhance rather than complicate societal outcomes,” Hayes-Mota writes.